Xingkerong Pharmaceutical (06833) announced the results for the year ended December 31, 2023. The group's beneficiaries...
According to the Zhitong Finance App, Xing Kerong Pharmaceutical (06833) announced the results for the year ended December 31, 2023. The group obtained revenue of RMB 2.54 billion (same unit), an increase of 11.82%; profit attributable to the owners of the company was RMB 42.352 million, a year-on-year decrease of 39.03%; profit per share was 0.021 yuan, and a final dividend of HK0.39 cents per share was proposed.
During the reporting period, the Group's gross profit increased by 17.4 million yuan to 323 million yuan (2022:305.9 million yuan), while gross margin decreased from 13.5% in 2022 to 12.7% during the reporting period. The increase in gross profit was mainly due to increased sales of human albumin and revenue from medical and aesthetic services.
During the reporting period, the Group's net profit decreased by 39.0% to 42.4 million yuan (2022:69.5 million yuan), mainly due to an increase in administrative expenses due to the Group's expansion of the business operations of the Pharmaceutical Research and Manufacturing Division and the Medical and Aesthetic Services Division.